CN-122005579-A - Application of minocycline in preparation of medicine for treating benign prostatic hyperplasia

Abstract

The invention provides application of minocycline in preparing a medicament for treating benign prostatic hyperplasia, and belongs to the technical field of biological medicines. The invention provides application of minocycline in preparing a medicament for treating benign prostatic hyperplasia, and provides a safe, convenient and efficient oral medicament treatment scheme for clinically treating benign prostatic hyperplasia, especially fibrosis pathological changes accompanied by benign prostatic hyperplasia. The proposal can directly aim at the core pathological links of diseases, realize the improvement and volume retraction of glandular tissue structure, thereby effectively relieving the symptom of urination obstruction of patients, avoiding the trauma and risk caused by operation treatment, greatly improving the accessibility of treatment and the compliance of patients, and having obvious clinical application value and market prospect.

Inventors

• HE SHENG
• Jia Kaiwen
• HE SEN
• XIE JUN
• LI RENKE
• YIN NAN
• SONG HUIFANG
• JIANG ZENGYU
• LI LU
• Feng Chengshuang

Assignees

• 山西医科大学第一医院

Dates

Publication Date

20260512

Application Date

20260211

Claims (10)

1. 1. Use of minocycline or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of benign prostatic hyperplasia.
2. 2. The use according to claim 1, wherein the benign prostatic hyperplasia is accompanied by interstitial fibrosis.
3. 3. The use according to claim 1 or 2, wherein the medicament is prepared in an oral dosage form.
4. 4. The use according to claim 3, wherein the oral dosage form is selected from the group consisting of tablets, capsules, granules, powders, pills, troches, oral solutions, syrups, oral suspensions and oral emulsions.
5. 5. Use of a pharmaceutical composition comprising minocycline or a pharmaceutically acceptable salt thereof as an active ingredient in combination with at least one pharmaceutically acceptable carrier or adjuvant for the manufacture of a medicament for the treatment of benign prostatic hyperplasia.
6. 6. The use according to claim 5, wherein the benign prostatic hyperplasia is accompanied by interstitial fibrosis.
7. 7. The use according to claim 5, wherein the auxiliary material comprises a filler, binder, disintegrant or lubricant.
8. 8. The use according to any one of claims 1 to 7, wherein the daily dose of the medicament is 50 mg to 200 mg in minocycline.
9. 9. A method of screening or evaluating a candidate drug for treating benign prostatic hyperplasia, comprising establishing an in vitro or in vivo screening model based on ZC3H12A-Th1-ifnγ -JAK/STAT signaling axis, and testing the activity of the candidate drug using the model; The establishment of the screening model comprises the steps of constructing a prostate cell model with ZC3H12A expression down-regulation or function deletion; the prostate cell model comprises prostate basal cells; The testing the activity of the candidate drug comprises detecting the effect of the candidate drug on the expression or activity of at least one molecule of ZC3H12A, IFN gamma, KRT14, ATF3, GPX3, STAT1 or STAT3 in the signal axis.
10. 10. A kit for screening or evaluating a candidate drug for treating benign prostatic hyperplasia, the kit comprising reagents for detecting the expression or activity of at least one molecule of ZC3H12A, IFN γ, KRT14, ATF3, GPX3, STAT1 or STAT 3.

Description

Application of minocycline in preparation of medicine for treating benign prostatic hyperplasia Technical Field The invention relates to the technical field of biological medicines, in particular to application of minocycline in preparing a medicament for treating benign prostatic hyperplasia. Background Benign prostatic hyperplasia (Benign Prostatic Hyperplasia, BPH) is a common urinary system disorder in middle-aged and elderly men, whose incidence increases significantly with age. The disease is mainly manifested by hyperplasia of prostatic epithelium and interstitial components, which leads to the increase of the volume of the prostate and further presses the urethra, thus causing a series of lower urinary tract symptoms such as frequent urination, urgent urination, difficult urination, thin urine flow and the like, and seriously affecting the life quality of patients. Pathologically, a significant portion of the proliferative tissue of BPH patients is not only enriched in cell numbers, but also accompanied by the development and progression of interstitial fibrosis. Fibrosis refers to the process of excessive deposition of extracellular matrix in tissue, loss of tissue elasticity, and increased stiffness. In the prostate, interstitial fibrosis is considered to be one of the important factors responsible for the decrease in gland elasticity, exacerbation of mechanical obstruction of the urethra and poor therapeutic efficacy of drugs. Thus, reversing or inhibiting prostate interstitial fibrosis has become an important target in the treatment of BPH. Currently, clinical treatment of BPH mainly follows the principle of stepping. For patients with mild to moderate, the first line regimen is drug therapy, and common drugs include alpha-blockers and 5 alpha-reductase inhibitors. The former improves symptoms mainly by relaxing smooth muscle of the prostate and bladder neck, while the latter reduces prostate volume by lowering in vivo androgen levels. However, both of these classes of drugs have very limited improvement in the already formed interstitial fibrotic tissue. For severe patients with poor drug treatment effects or complications, surgical operations such as transurethral prostatectomy are still current gold standard therapies. Although the surgical effect is definite, it is an invasive procedure, and there are risks of bleeding, infection, urethral stricture, urinary incontinence, and affected sexual function, etc., and not all patients can tolerate it. Therefore, the research and development of a therapeutic drug which can effectively interfere with the progress of prostatic fibrosis and can be administrated in a noninvasive manner has urgent needs and important significance for filling the blank of the current BPH clinical treatment and improving the prognosis of patients. Disclosure of Invention The invention aims to provide application of minocycline in preparing a medicament for treating benign prostatic hyperplasia, and solves the technical problem that the prior art lacks effective non-wound medicament for treating the benign prostatic hyperplasia accompanied by interstitial fibrosis. In order to achieve the above object, the present invention provides the following technical solutions: The invention provides application of minocycline or pharmaceutically acceptable salt thereof in preparing a medicament for treating benign prostatic hyperplasia. Preferably, in the above application, benign prostatic hyperplasia is accompanied by interstitial fibrosis. Preferably, in the above application, the medicament is prepared in an oral dosage form. Preferably, in the above application, the oral dosage form is selected from the group consisting of tablets, capsules, granules, powders, pills, lozenges, oral solutions, syrups, oral suspensions or oral emulsions. The invention also provides application of the pharmaceutical composition in preparing medicines for treating benign prostatic hyperplasia, wherein the pharmaceutical composition contains minocycline or pharmaceutically acceptable salts thereof as an active ingredient, and at least one pharmaceutically acceptable carrier or auxiliary material. Preferably, in the above application, benign prostatic hyperplasia is accompanied by interstitial fibrosis. Preferably, in the above application, the auxiliary material comprises a filler, a binder, a disintegrant or a lubricant. Preferably, in any of the above applications, the daily dosage of the medicament is 50mg to 200mg in terms of minocycline. The invention also provides a method for screening or evaluating a candidate drug for treating benign prostatic hyperplasia, which comprises the steps of establishing an in vitro or in vivo screening model based on ZC3H12A-Th 1-IFNgamma-JAK/STAT signal axis, testing the activity of the candidate drug by using the model, establishing a prostate cell model with ZC3H12A expression down-regulation or function deficiency, wherein the prostate cell model comprises pro